Targeted Liposomes Drug Delivery Market Analysis

Targeted Liposomes Drug Delivery Market Overview

Targeted Liposomes Drug Delivery Market Size was valued at USD 2.48 Billion in 2023. The Global Targeted Liposomes Drug Delivery industry is projected to grow from USD 2.67 Billion in 2024 to USD 4.93 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.97% during the forecast period (2024 - 2032).

May 2023: Gencor and Pharmako Biotechnologies have unveiled their latest liposome technology, which incorporates the scientifically validated PlexoZome technology. PlexoZome is a sophisticated liposomal technology designed for precise administration of liquid formulations. It is exclusively developed and produced on-site in its licensed facility. This technology allows for the customization and stability of liposomal contents. Liposomes are minuscule intricate entities enclosed by a lipid bilayer membrane that are imperceptible under a conventional light microscope. PlexoZomes formulations are confirmed using Transmission Electron Microscopy (TEM) and Cryo-TEM imaging, which are the exclusive methods for visualizing the liposome structure and their bilayer membrane structure. PlexoZome is manufactured in Pharmako's TGA-licensed facility, following rigorous GMP processes. It not only provides enhanced stability but also allows for customized particle size through Dynamic Light Scattering (DLS) validation.

Market Synopsis

Lately, the targeted liposomes drug delivery systems have played a significant role in the formulation of a potent drug to improve therapeutic outcomes in patients. The liposome formulations are targeted to reduce the toxicity and surge the accumulation at the target site. This mode of drug delivery lends high efficacy for the administration of various drug classes, such as anti-fungal, anti-viral, antimicrobial, anti-tubercular drugs, vaccines, and gene therapeutics. The increasing occurrences of chronic and life-threatening diseases push the demand for precise drug delivery mechanisms. This pushes the key players to come up with several innovations in the industry to withstand competitive pressure.

Market Influencer

The growing understanding of the heterogeneity of patients, the large variety of individual requirements within each given therapy, the rising awareness regarding the importance of a controlled release distribution, and the availability of the drug in the body, are some factors that are positively contributing to the growth of the Targeted Liposomes Drug Delivery Market.

Market Drivers

• The rising number of clinical trials. For instance, Bio-Path Holdings, Inc. has a drug candidate, BP1001, a liposomal Grb2 antisense oligonucleotide, for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that cannot or elect not to be treated with more intensive chemotherapy.

• Growing prevalence of chronic diseases such as cancer and fungal infections. More than 150 million people have serious fungal diseases worldwide, leading to an increasing patient pool. As a result, this leads to the growth of the Targeted Liposomes Drug Delivery Market.

• Increased demand for targeted drug delivery

• Increasing adoption of novel therapeutic approaches

• Increased understanding and awareness regarding the drug absorption and metabolism in the body

New product launches in recent years

• Joint ventures of prominent players

• Increasing government funding to support clinical trials

• High investment in research and development by pharmaceutical and biotechnology companies

Market Restraints

• High production cost

• Low solubility and short half-life of liposomes can negatively affect the preference rate, hindering the growth of the Targeted Liposomes Drug Delivery Market

Segmentation

Targeted Liposomes Drug Delivery Market By Type

• Liposomal Doxorubicin: Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer, so that more of the drug reaches the cancer cells. This type is used for the treatment of breast cancer, ovarian cancer, and multiple myeloma, among others. The increasing incidence rate of cancers is set to propel the growth of this market.

• Liposomal Paclitaxel: Liposomal Paclitaxel induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances the delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity. The high efficacy rate of this type pushes the demand for the use of this type. This results in the elevation of this segment.

• Liposomal Amphotericin B: Liposomal Amphotericin B is used in the treatment of various fungal and parasitic infections. The increasing fungal infection patient pool is driving the growth of this segment.

• Others: The other segment includes folate targeted liposomes and others.

Targeted Liposomes Drug Delivery Market By Application

• Fungal Infection Therapy: Liposomal products, such as Amphoteric and AmBisome is developed for fungal infections. Increasing the prevalence of fungal infections is likely to drive the segment growth in the future.

• Cancer Therapy (Tumor Therapy): Cancer therapy using liposomes uses a targeted liposome drug delivery system. Doxil and Myocet, among others, are injectable polymeric nanoparticle drug formulations that utilize doxorubicin drug for the treatment of cancer.

• Others: Liposomes have become an important carrier system for vaccine development and gene therapeutics, among others.

Targeted Liposomes Drug Delivery Market By Region

• Americas: The Americas is estimated to be the largest regional market owing to increasing strategic initiatives, such as mergers, acquisitions, agreements, and joint ventures, employed by major players in the targeted liposomes drug delivery industry. For instance, in February 2020, Catalent, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, completed its acquisition of MaSTherCell Global Inc. Such steps promise the growth of the targeted liposomes drug delivery market in the Americas at a substantial rate in the near future.

• Europe: The European region holds the second largest share as there is increasing support from regulatory authorities, as well as increasing awareness created by key players in the market. Also, a lot of key players, such as Lonza (Switzerland), Merck KGaA (Germany), Vetter (Germany), Recipharm AB (Sweden), and Fareva (France), are based in major European countries, which further pushes the growth of the targeted liposomes drug delivery market in this region.

• Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the targeted liposomes drug delivery market. This region is witnessing a surge as major companies are actively involved in expanding their reach by entering into joint ventures, partnerships, collaborations, and agreements. For instance, in November 2019, Recipharm AB (Austria) expanded its Indian injectable dosage form capabilities through a partnership with the Sobti family aimed at creating production capacity in India for a range of sterile dosage forms.

• Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to innovative solutions.

Key Players

• Catalent (US)


• Pacira Pharmaceuticals, Inc. (US)


• Baxter (US)


• Lonza (Switzerland)


• Evonik (Germany)


• Merck KGaA (Germany)


• Fareva (France)


• Vetter (Germany)


• Polymun Scientific Immunbiologische Forschung GmbH (Austria)


• Recipharm AB (Sweden)


• Dalton Pharma Services (Canada)

Recent Development

October 2023: Nanobiotix announces the launch of its new NBTXR3 targeted liposome drug delivery system. NBTXR3 is designed to deliver the drug doxorubicin to cancer cells more effectively, while reducing the side effects of chemotherapy. NBTXR3 targeted liposome drug delivery systemOpens in a new windowStealth BioTherapeutics announces the launch of its new TriSpiration™ targeted liposome drug delivery system. TriSpiration™ is designed to deliver multiple drugs to cancer cells simultaneously, which can improve the efficacy of cancer treatment. TriSpiration™ targeted liposome drug delivery systemOpens in a new windowAvidity Biosciences announces the launch of its new ARC-101 targeted liposome drug delivery system. ARC-101 is designed to deliver the drug doxorubicin to cancer cells more effectively, while also delivering a second drug that inhibits tumor resistance. 

September 2023: The FDA approves Nanobiotix's NBTXR3 targeted liposome drug delivery system for the treatment of soft tissue sarcoma. This is the first FDA-approved targeted liposome drug delivery system for the treatment of cancer. The European Medicines Agency (EMA) grants orphan drug designation to Stealth BioTherapeutics' TriSpiration™ targeted liposome drug delivery system for the treatment of triple-negative breast cancer. This designation gives Stealth BioTherapeutics access to funding and support from the EMA to accelerate the development of TriSpiration™. Avidity Biosciences announces that it has raised $100 million in Series A funding to support the development of its ARC-101 targeted liposome drug delivery system. This funding will help Avidity Biosciences to advance ARC-101 into clinical trials.